// App-Quantinova.ai

: Two Weeks of Low Molecular Weight Heparin for Isolated Symptomatic Distal Vein Thrombosis (TWISTER Study): Interim Analysis of First 200 Patients

Researchers

Presenter

  • E. Merriman

Principal Investigators

  • S. Chunilal

  • S. McRae

  • T. Brighton

  • P. Ockelford

  • H. Tran

  • J. Curnow

  • V. Chen

  • B. Chong

  • M. Smith

  • G. Royle

  • H. Crowther

  • A. Slocombe

  • A. Cummins

Medical Centers

  • North Shore Hospital, Haematology, Auckland, New Zealand

  • Monash Medical Centre, Haematology Research, Melbourne, Australia

  • Royal Adelaide Hospital, Adelaide, Australia

  • Prince of Wales Hospital, Sydney, Australia

  • Auckland City Hospital, Auckland, New Zealand

  • Frankston Hospital, Haematology, Melbourne, Australia

  • Westmead Hospital, Haematology, Sydney, Australia

  • Concord Hospital, Cardiology, Sydney, Australia

  • St George's Hospital, Haematology, Sydney, Australia

  • Christchurch Hospital, Haematology, Christchurch, New Zealand

  • Middlemore Hospital, Auckland, New Zealand

  • Blacktown Hospital, Haematology, Sydney, Australia

  • Box Hill Hospital, Haematology, Melbourne, Australia

  • Monash Medical Centre, Haematology Research, Melbourne, Australia

  • Alfred Hospital, Gastroenterology, Melbourne, Australia

  • Australian Centre for Blood Diseases, Melbourne, Australia

Locations

  • New Zealand

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

  • Pulmonary embolism

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Enoxaparin

  • Enoxaparin sodium

  • Heparin

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved